growth factor receptor bound protein 7Genealiases: []
Q-omics provides the consensus-scored GRB7 profile across patient tissues and cancer cell-line models. GRB7 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in PAAD. Among the 18 cancer types available for tumor–normal comparison, GRB7 is differentially expressed in 15, with the highest sampling consensus in COAD. Additionally, GRB7 RNA expression shows 17,429 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight PAAD, COAD, and KIRP as cancer lineages where GRB7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GRB7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GRB7 survival associations across molecular data types. GRB7 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (2) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GRB7 RNA expression–survival associations across cancer types. High GRB7 expression shows unfavorable associations in PAAD, OV and LGG, but favorable associations in ACC, KIRC and MESO. The PAAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify PAAD as the clearest survival context for GRB7 RNA expression.
This table summarizes GRB7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 6. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for GRB7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GRB7 shows lower tumor expression in KIRC and KICH and higher tumor expression in COAD, THCA, STAD and BLCA. The COAD box plot shows higher GRB7 RNA expression in tumor versus normal tissue (log2 FC = +2.761, t-test p < 0.001).
This table shows molecular features associated with GRB7 in patient tissues and cancer cell lines. In patient samples, GRB7 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, GRB7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in BONE and LUNG_SCLC.
